エトドラク
1,8-ジエチル-1,3,4,9-テトラヒドロピラノ[3,4-b]インドール-1-酢酸 · R-エトドラック · (1R)-1,8-ジエチル-1,3,4,9-テトラヒドロピラノ[3,4-b]インドール-1β-酢酸 · エトドラク · (+)-1,8-ジエチル-1,3,4,9-テトラヒドロピラノ[3,4-b]インドール-1-酢酸 · (-)-エトドラック · (1R)-1,8-ジエチル-1,3,4,9-テトラヒドロピラノ[3,4-b]インドール-1-酢酸 · (±)-エトドラック
識別子と物理属性
| CAS No. | 41340-25-4 |
|---|---|
| 分子式 | C17H21NO3 |
| 平均分子量 | 287.35 g/mol |
| 単同位体質量 | 287.15214353 g/mol |
| SMILES | CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3 |
| InChIKey | NNYBQONXHNTVIJ-UHFFFAOYSA-N |
| PubChem CID | 3308 |
| ChEMBL | CHEMBL622 |
| ChEBI | CHEBI:4909 |
| EC No. | 629-689-1 |
| DTXSID | DTXSID9020615 |
| 現地名 | エトドラク |
化学・物理的性質
| XLogP | 2.8 |
|---|---|
| 極性表面積 | 62.3 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 3 |
| 回転可能結合数 | 4 |
| 重原子数 | 21 |
| 形式電荷 | 0 |
| 複雑度 | 399 |
| 医薬品 | DEA NFLIS-Drug Category -> AnalgesicsPharmaceuticalsPharmaceuticals -> Used in Switzerland |
| LogP（分配係数） | 2.52.75 |
| 溶解度 | 3.92e-02 g/L水にほとんど溶けず、アセトンとエタノールに溶けやすい (96%)40mg/L(37℃) |
| Human Drugs | Breast FeedingLactationMilk, HumanAnalgesic AgentsAnti-inflammatory Agents, NonsteroidalFDA approved drugs -> Active ingredientPharmaceuticals |
| Animal Drugs | Active Ingredients (Etodolac) -> FDA Greenbook |
| 融点 | 145 - 148 °C145-1480C |
| Physical Description | Solid |
| Dissociation Constants | 4.65 |
| Collision Cross Section | 164.4 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]163.36 Ų [M+H]+ [CCS Type: TW |
| 沸点 | 507.9±45.0 °C(Predicted) |
| 密度 | 1.193±0.06 g/cm3(Predicted) |
| 貯蔵条件 | 2-8°C |
| 外観・状態 | Solid |
| pKa（酸解離定数） | 4.65(at 25℃) |
| 色 | White to Orange to Green |
| Merck | 14,3874 |
| BCS Class | 2 |
| 主な用途 | 医薬品（低分子化合物） |
| InChI | 1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20) |
| InChIKey | NNYBQONXHNTVIJ-QGZVFWFLSA-N |
| SMILES | CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12 |
| CAS データベース | 41340-25-4(CAS DataBase Reference) |
| EPAの化学物質情報 | Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (41340-25-4) |
化学的特性
Crystalline Solid
安全性と法規制
| GHS 分類 | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P203, P264, P264+P265, P270, P280, P301+P316, P305+P351+P338, P318, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 50 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 規制情報 | Hazard Traits - Developmental ToxicityReproductive ToxicityEtodolac: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Hepatotoxicity | Prospective studies show that 1% to 2% of patients taking etodolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (greater than 3 fold elevated) occur in less than 1% of patients. |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)EtodolacvMost-DILI-concern8Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation◈ What is etodolac? |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | UQ0360000 |
| 輸送番号（UN） | 3249 |
| 税関コード | 29349990 |
| 危険文句（R） | 23/24/25-40-36-25-36/37/38 |
| 危険表示 | T,Xi |
| 安全措置（S） | 22-36-45-26-36/37 |
| 危険等級 | 6.1(b)Acute Tox. 3 Oral |
用途
用途
ピラノ酢酸系化合物です。シ クロオキシゲナーゼ2（COX-2）を選択的に 阻害します。
用途
インドール酢酸系化合物です。シクロオキシゲナーゼ-IIを選択的に阻害する作用を示します。
説明
Etodolac (etodolic acid) is a non-steroidal antiinflammatory/analgesic agent useful in the treatment of various inflammatory conditions, including rheumatoid and osteoarthritis.
使用
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Etodolac displays anti-inflammatory effects in both adjuvant arthritic and normal rats. E todolac is an anti-inflammatory; analgesic.
一般的な説明
Etodolac (Lodine, Ultradol), a chiral, COX-2 selectiveNSAID drug that is marketed as a racemate, possesses an indolering as the aryl portion of this group of NSAID drugs.It shares many similar properties of this group and is indicatedfor short- and long-term management of pain and OA.Similar to ketorolac, etodolac exhibits several uniqueenantioselective pharmacokinetic properties. For example,the “inactive” (R)-enantiomer has approximately a 10-foldhigher plasma concentration than the active (S)-enantiomer.Furthermore, the active (S)-enantiomer is less protein boundthan its (R)-enantiomer and therefore has a very large volumeof distribution. It is well absorbed with an elimination halflifeof 6 to 8 hours. Etodolac is extensively metabolized intothree major inactive metabolites, 6-hydroxy etodolac (via aromatichydroxylation), 7-hydroxy-etodolac (via aromatic hydroxylation),and 8-(1'-hydroxylethyl) etodolac (via benzylichydroxylation), which are eliminated as the correspondingether glucuronides. Its unstable, acyl glucuronide, however,is subject to enterohepatic circulation and reactivation tothe parent drug, similar to other NSAIDS in this class.